![Ingmar Bruns](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ingmar Bruns
Hoofd Techniek/Wetenschap/O&O bij
ZENTALIS PHARMACEUTICALS, INC.
Vermogen: 100 072 $ op 31-05-2026
Profiel
Ingmar Bruns is currently the Chief Medical Officer at Zentalis Pharmaceuticals, Inc. He previously held the position of Chief Medical Officer at Trillium Therapeutics, Inc. from 2020 to 2021.
He also worked as the Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns obtained a doctorate degree from Universität zu Lübeck.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-04-2026 | 25.018 ( 0,04% ) | 100 072 $ | 31-05-2026 |
Actieve functies van Ingmar Bruns
| Bedrijven | Functie | Begin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 13-11-2024 |
Eerdere bekende functies van Ingmar Bruns
| Bedrijven | Functie | Einde |
|---|---|---|
| TRILLIUM THERAPEUTICS | Hoofd Techniek/Wetenschap/O&O | 17-11-2021 |
| PIERIS PHARMACEUTICALS | Corporate Officer/Principal | - |
Opleiding van Ingmar Bruns
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
9
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Universität zu Lübeck
 Universität zu Lübeck Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
